---
title: "Top 10 热门中概股涨跌幅（10月13日）"
description: "嘉楠科技 (CAN) 涨 39.45%，成交额 1.2 亿美元，年内累计跌 25.9%。 天境生物 (IMAB) 涨 21.38%，成交额 2636.9 万美元，年内累计涨 581.2%。 Mercurity Fintech(MFH) 跌 21.28%，成交额 1425.9 万美元，年内累计涨 165.7%。 宏力集团 (HLP) 跌 9.09%，成交额 121.5 万美元，年内累计涨 14.5%"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260944052.md"
published_at: "2025-10-13T22:01:01.000Z"
---

# Top 10 热门中概股涨跌幅（10月13日）

> 嘉楠科技 (CAN) 涨 39.45%，成交额 1.2 亿美元，年内累计跌 25.9%。 天境生物 (IMAB) 涨 21.38%，成交额 2636.9 万美元，年内累计涨 581.2%。 Mercurity Fintech(MFH) 跌 21.28%，成交额 1425.9 万美元，年内累计涨 165.7%。 宏力集团 (HLP) 跌 9.09%，成交额 121.5 万美元，年内累计涨 14.5%。

纳斯达克综合指数涨 2.21%，年内累计涨 17.5%；标普 500 指数涨 1.56%，年内累计涨 13.1%；道琼斯指数涨 1.29%，年内累计涨 8.3%。

嘉楠科技 (CAN) 涨 39.45%，成交额 1.2 亿美元，年内累计跌 25.9%。

天境生物 (IMAB) 涨 21.38%，成交额 2636.9 万美元，年内累计涨 581.2%。

Mercurity Fintech(MFH) 跌 21.28%，成交额 1425.9 万美元，年内累计涨 165.7%。

宏力集团 (HLP) 跌 9.09%，成交额 121.5 万美元，年内累计涨 14.5%。

### Related Stocks

- [CAN.US - 嘉楠科技](https://longbridge.com/zh-CN/quote/CAN.US.md)
- [IMAB.US - 天境生物](https://longbridge.com/zh-CN/quote/IMAB.US.md)
- [MVST.US - Microvast](https://longbridge.com/zh-CN/quote/MVST.US.md)
- [MLGO.US - MicroAlgo](https://longbridge.com/zh-CN/quote/MLGO.US.md)
- [VNET.US - 世纪互联](https://longbridge.com/zh-CN/quote/VNET.US.md)
- [MFH.US - Mercurity Fintech](https://longbridge.com/zh-CN/quote/MFH.US.md)
- [HLP.US - 宏力集团](https://longbridge.com/zh-CN/quote/HLP.US.md)
- [MLCO.US - 新濠博亚娱乐](https://longbridge.com/zh-CN/quote/MLCO.US.md)
- [NIU.US - 小牛电动](https://longbridge.com/zh-CN/quote/NIU.US.md)
- [TUYA.US - 涂鸦智能](https://longbridge.com/zh-CN/quote/TUYA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric Cancer | I-MAB has announced promising Phase I data for Givastomig, a bispecific antibody targeting Claudin 18.2, in advanced gas | [Link](https://longbridge.com/zh-CN/news/262671237.md) |
| I-Mab Sponsored ADR (NASDAQ:IMAB) Receives Consensus Rating of "Moderate Buy" from Brokerages | I-Mab Sponsored ADR (NASDAQ:IMAB) has received a consensus rating of "Moderate Buy" from eight brokerages. One analyst r | [Link](https://longbridge.com/zh-CN/news/263045964.md) |
| I-Mab Announces Strategic Transformation and Rebranding to NovaBridge Biosciences | I-Mab has announced a strategic transformation to become NovaBridge Biosciences, pending shareholder approval. The compa | [Link](https://longbridge.com/zh-CN/news/261504233.md) |
| I-Mab Reports H1 2025 Financial Results Amid Strategic Shift | I-Mab (IMAB) reported its H1 2025 financial results on October 6, 2025, amid a strategic shift involving the divestiture | [Link](https://longbridge.com/zh-CN/news/260044858.md) |
| Melco Resorts & Entertainment (MLCO) Is Down 12.9% After Return To Quarterly Profitability And Record Five-Star Awards | Melco Resorts & Entertainment reported a Q4 2025 revenue of $1.29 billion, swinging to a $60.64 million profit from a pr | [Link](https://longbridge.com/zh-CN/news/276002958.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。